Stock comparison
Genmab A/S
Stryker
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.47B
Sector
Healthcare
SYK
Stryker
Market cap
$121.8B
Sector
Healthcare
Overall winner
Stryker SYK
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | SYK | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 65B | Tie |
| Benjamin Graham | 64C | 83A | SYK |
| Philip Fisher | 48D | 67C | SYK |
| Peter Lynch | 25F | 68B | SYK |
| Joel Greenblatt | 76B | 50D | GMAB |
| Charlie Munger | 68C | 63D | GMAB |
| Terry Smith | 71C | 62D | GMAB |
Side-by-side metrics
| Metric | GMAB | SYK |
|---|---|---|
| Market cap | $16.47B | $121.8B |
| P/E (TTM) | 6.2x | 35.2x |
| EV/EBIT | 12.0x | 26.4x |
| ROIC (TTM) | 43.78% | 9.79% |
| Gross margin | 93.88% | 63.67% |
| Net margin | 18.23% | 13.21% |
| Revenue CAGR 5y | -18.45% | 10.07% |
| EPS CAGR 5y | -23.48% | 12.55% |
| Debt / Equity | 0.1x | 0.6x |
| Dividend yield | 0.0% | 1.12% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 0.6x+88%
- P/E (TTM)6.2xvs 35.2x+83%
- ROIC (TTM)43.78%vs 9.79%+78%
- EV/EBIT12.0xvs 26.4x+55%
SYK leads on
- Revenue CAGR 5y10.07%vs -18.45%+155%
- EPS CAGR 5y12.55%vs -23.48%+153%
- Dividend yield1.12%vs 0.0%+100%
- Market cap$121.8Bvs $16.47B+86%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.